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Abstract
Background: Access to artemisinin-based combination therapy (ACT) remains limited in high malaria-burden
countries, and there are concerns that the poorest people are particularly disadvantaged. This paper presents new
evidence on household treatment-seeking behaviour in six African countries. These data provide a baseline for
monitoring interventions to increase ACT coverage, such as the Affordable Medicines Facility for malaria (AMFm).
Methods: Nationally representative household surveys were conducted in Benin, the Democratic Republic of
Congo (DRC), Madagascar, Nigeria, Uganda and Zambia between 2008 and 2010. Caregivers responded to
questions about management of recent fevers in children under five. Treatment indicators were tabulated across
countries, and differences in case management provided by the public versus private sector were examined using
chi-square tests. Logistic regression was used to test for association between socioeconomic status and 1) malaria
blood testing, and 2) ACT treatment.
Results: Fever treatment with an ACT is low in Benin (10%), the DRC (5%), Madagascar (3%) and Nigeria (5%), but
higher in Uganda (21%) and Zambia (21%). The wealthiest children are significantly more likely to receive ACT
compared to the poorest children in Benin (OR = 2.68, 95% CI = 1.12-6.42); the DRC (OR = 2.18, 95% CI = 1.12-
4.24); Madagascar (OR = 5.37, 95% CI = 1.58-18.24); and Nigeria (OR = 6.59, 95% CI = 2.73-15.89). Most caregivers
seek treatment outside of the home, and private sector outlets are commonly the sole external source of
treatment (except in Zambia). However, children treated in the public sector are significantly more likely to receive
ACT treatment than those treated in the private sector (except in Madagascar). Nonetheless, levels of testing and
ACT treatment in the public sector are low. Few caregivers name the national first-line drug as most effective for
treating malaria in Madagascar (2%), the DRC (2%), Nigeria (4%) and Benin (10%). Awareness is higher in Zambia
(49%) and Uganda (33%).
Conclusions: Levels of effective fever treatment are low and inequitable in many contexts. The private sector is
frequently accessed however case management practices are relatively poor in comparison with the public sector.
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Supporting interventions to inform caregiver demand for ACT and to improve provider behaviour in both the
public and private sectors are needed to achieve maximum gains in the context of improved access to effective
treatment.
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Background
In malaria endemic settings, children under five are parti-
cularly vulnerable to severe disease and death when
infected with malaria. Decisions made by children’s care-
givers at the first signs of potential malaria infection
(fever) are critical to ensure child health and survival.
Studies of treatment-seeking behaviour illustrate the var-
ied, complex and iterative processes undertaken by care-
givers to address fever in children. Most children receive
some form of treatment, most often beginning with treat-
ment outside of the formal health care system (e.g. phar-
macies, drug shops). In the course of treating a fever
episode, multiple treatments are often acquired from a
variety of sources [1-3]. In recent years, caregivers have
faced new challenges to acquire effective anti-malarial
medicines for their children. Cheap and widely available
medicines previously relied upon to treat malaria in chil-
dren, such as chloroquine, are no longer effective. Fol-
lowing guidance from the World Health Organization, by
2009 the vast majority of Plasmodium falciparum malaria
endemic countries and territories had adopted artemisi-
nin combination therapy (ACT) as national first-line
treatments for uncomplicated malaria [4].
Although national policies have changed, use of ACT
remains limited in high-burden countries [5]. Results
from nationally representative outlet surveys in six sub-
Saharan countries (Benin, the Democratic Republic of
Congo, Madagascar, Nigeria, Uganda, and Zambia) sug-
gest that when caregivers arrive at outlets searching for
fever treatment, they are unlikely to find ACT that they
can afford, if they can find ACT at all [6]. While the
majority of public and private sector medicine outlets
stock anti-malarials, ACT availability is low, particularly
in the private sector. In the private sector, quality-
assured, first-line ACT is typically six to 21 times as
expensive as the most commonly sold/distributed anti-
malarial (always a non-artemisinin monotherapy). While
availability is generally higher and price generally lower
for ACT treatment in the public sector, national sales
volume data suggest that the majority of anti-malarial
medicines move through the private sector in all coun-
tries except Zambia. Market share data also indicate
that most anti-malarial medicines sold or distributed in
these countries are non-artemisinin monotherapies, such
as chloroquine [6].
Financing for malaria control has increased substan-
tially over the last decade. Increased donor and national
government spending has facilitated, among other inter-
ventions, introduction of rapid diagnostic tests (RDTs)
for malaria and ACT treatment. Strategies adopted to
improve ACT coverage and use include improved sup-
ply of free or heavily subsidized RDTs and pre-packaged
ACT in the public and private sectors; public provider
training; and behaviour change communication cam-
paigns promoting diagnosis and ACT treatment [7].
One of the global initiatives currently underway is the
Affordable Medicines Facility-malaria (AMFm), which
aims to expand access to affordable ACT. The AMFm
seeks to reduce consumer prices through price negotia-
tions and a buyer co-payment for which both public and
private first-line buyers at the country level are eligible.
Reduced prices are expected to extend down the anti-
malarial supply chain so that when children’s caregivers
seek fever treatment at a given outlet, they are more
likely to find effective medicines that they can afford.
Changes in household treatment-seeking behaviour and
improved household fever management are expected as
access to effective anti-malarials increases. It is further
expected that improving access through both public and
private sector channels will lead to improvements in
fever treatment among children of all socioeconomic
backgrounds. The first phase of the AMFm began in
2010; it will operate in eight countries (Cambodia,
Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania
and Uganda) for 24 months during which time it is
being independently evaluated [8].
This study uses data from household surveys underta-
ken by ACTwatch [9]. ACTwatch employs standardized
methodologies and questionnaires to monitor national
availability, price, volumes and demand for ACT [10].
The data allow comparison of ACT use across countries
and provide a baseline for monitoring the success of
interventions to increase access such as the AMFm.
Three of the six African ACTwatch countries are
AMFm countries (Madagascar, Nigeria and Uganda),
providing the potential to compare countries with and
without the subsidy programme over time. This paper
presents results from nationally representative house-
hold surveys undertaken in Benin, the Democratic
Republic of Congo (DRC), Madagascar, Nigeria, Uganda
and Zambia between 2008 and 2010, providing data on
caregiver behaviour in high malaria burden contexts
prior to significant scale-up of affordable ACT. In addi-
tion to providing country baselines for monitoring the
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success of interventions to increase access, these results
can also be used to inform the design and implementa-
tion of supporting interventions.
Methods
Design and sampling
Nationally representative samples were selected using
multi-stage cluster sampling, with clusters selected with
probability proportional to population size (PPS), irre-
spective of cluster fever prevalence or estimated number
of fevers per cluster. Equal allocation stratification was
utilized to allow for strata comparisons, with different
strata used depending on the country context. In Mada-
gascar and Zambia, stratification was conducted with
urban and rural domains. In the DRC, the sample was
stratified across four geographic regions, and in Nigeria,
across six geo-political regions. In Uganda, two strata
were included for low/moderate and high malaria trans-
mission areas. In Benin, a single domain was used.
Within each stratum, 19 sub-districts were selected with
PPS from a list of all sub-districts. At the second stage,
five enumeration areas (EA) were selected with PPS.
The estimated fever prevalence was used to identify the
number of households necessary to screen in order to
yield the desired number of children with fever. House-
hold sampling frames were not available and therefore,
estimated cluster size (obtained from official population
listings in each country) was used to identify a sampling
interval for systematic random sampling of households
within each cluster. A random start household was
selected, and the cluster-specific sampling interval was
used to guide interviewers in random selection of
households (i.e. by walking in a randomly selected direc-
tion from the random start household and selecting
every nth household according to the sampling interval).
Selected households were screened to identify fevers
among children under five that occurred in the two
weeks preceding the survey. Specifically, a household
representative was asked if the household: 1) contained
any children under the age of five; and 2) if any of these
children had fever during the two weeks preceding the
survey. Households with a recently febrile child were
included in the study. The total number of households
and febrile children included in the study are as follows:
Benin, 876 households, 927 children; the DRC, 2, 236
households, 2, 665 children; Madagascar, 1, 961 house-
holds, 2, 120 children; Nigeria, 2, 734 households, 3, 274
children; Uganda, 1, 509 households, 1, 752 children;
and Zambia, 1, 703 households, 1, 885 children.
Training and fieldwork
Data collection teams received a five or six-day training
focused on administration of the questionnaire and sam-
pling procedures. Data were collected during peak
malaria transmission seasons corresponding with the
primary rainy seasons in Benin (April-May 2009); the
DRC (April-June, 2010); Madagascar (December 2008-
January 2009); Nigeria (August-September, 2009);
Uganda (March-April, 2009); and Zambia (April-July,
2009). Caregivers of children under five with fever in
the two weeks preceding the survey were invited to par-
ticipate in the study. Respondents were selected based
on their responsibilities as primary caregiver for the
child with fever (i.e. responsible for daily care of the
child including supervision, bathing and feeding). These
primary caregivers were typically the child’s mother with
the exception of orphaned and foster children. An inter-
view lasting approximately one hour was conducted
among women that provided informed consent. All
questionnaires were reviewed by the team supervisor
and at least 20% of all households were re-visited by a
supervisor for quality control. Microsoft Access (©
Microsoft Corporation, Seattle, WA, USA) was used for
double data entry and validation in each country, with
the exception of Madagascar, where personal digital
assistants programmed using Visual CE software (©
Syware, Cambridge, MA, USA) were used for data col-
lection and Microsoft Access for data management. All
research activities operated under ethical approval
granted by national ethics review boards.
Materials
Caregivers responded to a series of questions about
management of fevers that had occurred among children
in their care in the two weeks preceding the survey.
Questions documented the type, timing, source and cost
of treatments acquired for the child’s fever. Caregiver
recall and recognition of the type of treatment acquired
was aided by the use of a comprehensive anti-malarial
field guide with photographs and brand names of com-
mon anti-malarials available in public and private sector
outlets. A household questionnaire module, modelled
after the Demographic and Health Survey (DHS) col-
lected information on housing characteristics and house-
hold assets to be used in assessment of relative
socioeconomic status [11].
Measures
Indicators of treatment-seeking behaviour and treatment
of fever were constructed for each country from care-
giver reports on treatment sources; type of treatments
acquired (brand names); timing of treatments given to
the child; and whether or not the child received a diag-
nostic blood test for malaria. Brand names were used to
categorize drugs according to generic anti-malarial types
(e.g. chloroquine, quinine, artemether-lumefantrine).
These were then further classified as artemisinin combi-
nation therapy (ACT), artemisinin monotherapy, or
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non-artemisinin monotherapy. Indicators were calcu-
lated using the three classes of anti-malarials above, as
well as an overall category for any anti-malarial. Con-
sistent with indicators calculated by the DHS and
Malaria Indicator Surveys (MIS), anti-malarial (and
ACT) treatment received the same or next day after
onset of fever was used as a proxy measure for treat-
ment within 24 hours of onset of fever and is considered
prompt treatment.
Treatment sources were categorized as either public/
not for profit or private sector. Public health facilities
(PHFs), community health workers (CHWs) and non-
profit health facilities were classified as public/not for
profit sector, with PHFs constituting the majority of this
category. The private sector encompasses outlets with or
without qualified health workers (e.g. licensed pharma-
cies as well as unlicensed drug shops). While treatment-
seeking indicators for the fever episode were calculated
for each child, anti-malarial type and source were calcu-
lated at the drug level as some children received more
than one drug to treat one fever episode.
Socioeconomic status was assessed for each household
relative to other households using measures of housing,
water, sanitation and household asset items modelled
after the DHS. A wealth index was constructed from the
individual indicators, which were assigned a weight
through principal components analysis and standardized
in relation to a standard normal distribution. Each child
was categorized according to the value of their house-
hold’s wealth index, and placed in one of five wealth
quintiles, ranging from poorest to least poor [12].
Data analysis
All analyses were performed using individual datasets
for each country. Frequencies were tabulated for treat-
ment-seeking and fever treatment indicators. The pro-
portion of children receiving any anti-malarial, an ACT
treatment, and a malaria blood test were calculated for
each sector. Differences in proportions between sectors
were examined using the chi-square test of association.
Logistic regression was used to test for an association
between household socioeconomic status and 1) ACT
treatment, and 2) diagnostic testing. Odds ratios and
95% confidence intervals are reported. Data were
weighted to account for difference in the probability of
being selected in the different strata. Standard error esti-
mation accounted for clustering at the sub-district clus-
ter and EA levels. Stata 11.0 (© Stata Corp, College
Station, TX, USA) was used for all analysis.
Results
Sources of fever treatment
Table 1 summarizes treatment-seeking behaviour for
children with fever. Caregivers typically respond to fever
with some form of treatment, and in some cases treat-
ment is sought from multiple sources. The most com-
mon initial response is to visit a private sector outlet in
the DRC (51%), Madagascar (53%), Nigeria (46%) and
Uganda (42%). By contrast, only 18% of children with
fever are initially taken to the private sector in Zambia,
where caregivers most commonly initially seek treat-
ment from the public sector (50%). In Benin, caregivers
are most likely to initially treat the child at home (44%);
this is also a relatively common practice in the DRC
(23%), Nigeria (32%), Uganda (38%) and Zambia (25%).
Most caregivers eventually seek treatment outside of
the home during the course of a fever episode (the
DRC, 73%; Madagascar, 78%; Nigeria, 73%; Uganda,
72%; Zambia, 77%). The exception is Benin where care-
givers of only half of children with fever seek treatment
outside of the home. When seeking treatment outside of
the home, caregivers typically visit only one source. The
private sector as the sole external source of treatment is
far more common than the public sector in the DRC
(74% vs 23%), Madagascar (68% vs 29%), Nigeria (69% vs
26%) and Uganda (68% vs 27%). In Benin, sole treatment
outside the home is divided between private (55%) and
public (40%) sectors. In Zambia, most caregivers visiting
external sources seek treatment in the public sector only
(72%) (Table 1).
Among children who receive care at any time during
the illness episode, treatment-seeking within the public
sector almost always entails a public health facility;
CHWs are the source of treatment for fewer than 10%
of the children who receive care in the public sector
(Benin, 1%; the DRC, 0%; Madagascar, 5%; Nigeria, 5%;
Uganda, 9%; Zambia, 2%) (Table 1). Treatment-seeking
in the private sector varies by country. Pharmacies and
drug shops are the source of treatment for most of the
children who receive care in the private sector in the
DRC (70%), Madagascar (52%) and Nigeria (82%). In
Uganda, private health facilities are the predominant
source of treatment for children who receive care in the
private sector (74%). Other private outlets, such as
kiosks, shops and mobile vendors, are the most com-
mon source of treatment for children who receive care
in the private sector in Benin (71%) and Zambia (57%)
(Table 1).
Diagnosis and treatment of children with fever
Fewer than 10% of children with fever receive a diagnos-
tic blood test for malaria (RDT or microscopy) in Benin
(4%), Madagascar (6%) and Nigeria (6%). Diagnosis is
slightly more common in the DRC (15%) and Uganda
(11%), and in Zambia nearly one-third of children with
fever receive a malaria diagnosis (31%) (Figure 1).
Similar levels of anti-malarial treatment for fever are
found in Benin (41%), the DRC (43%), Madagascar
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(47%) and Zambia (39%). In Nigeria, only 33% of chil-
dren receive anti-malarial treatment and in Uganda,
over half receive an anti-malarial (52%). ACT treatment
is very low in Benin (10%), the DRC (5%), Madagascar
(3%) and Nigeria (5%), but relatively higher in Uganda
(21%) and Zambia (21%). When acquired, ACT and
other anti-malarial treatments are often provided for
children within the same or next day after onset of fever
(Figure 1).
Type and source of anti-malarials acquired for children
Non-artemisinin monotherapies are the most commonly
acquired anti-malarial drugs for children under five in
Benin (76%), the DRC (84%), Madagascar (93%), Nigeria
(81%), and Uganda (63%). The most common non-arte-
misinin monotherapies are chloroquine (Benin, Mada-
gascar, Nigeria), quinine (the DRC, Uganda), and
sulphadoxine/pyrimethamine (SP) (Zambia). While just
over half of all anti-malarials acquired for children in
Zambia are ACT (53%), ACT makes up a relatively
small proportion of all anti-malarial treatments acquired
for children in Benin (23%), the DRC (10%), Madagascar
(3%), Nigeria (13%) and Uganda (36%). Artemisinin
monotherapies make up 1% or less of anti-malarials
acquired in all countries except the DRC (6%) and
Nigeria (6%) (Figure 2). Most ACT acquired for children
are first-line treatments: Benin, 83%; the DRC, 68%;
Madagascar, 77%; Nigeria, 88%; Uganda, 100%; and
Zambia, 100% (Table 2).
The private sector is the source of about half or more
of the anti-malarial treatments acquired in the DRC
(67%), Madagascar (62%), Nigeria (47%) and Uganda
(53%) (Figure 3). Pharmacies and drug stores are the
most common private sector source of anti-malarials in
the DRC (50% of all treatments acquired), Madagascar
(33%), and Nigeria (37%). In Uganda, the most common
private sector source is private health facilities (43%). In
Zambia, the public sector accounts for 87% of anti-
Table 1 Treatment-seeking behaviour for children under five with fever in the past two weeks (%)
Benin DRC Madagascar Nigeria Uganda Zambia
N =
926
N = 2,
661
N = 2, 120 N = 3,
247
N = 1,
695
N = 1,
877
Initial treatment-seeking behaviour
Did not seek treatment 17.4 9.4 9.5 4.8 4.5 8.0
At home 44.2 23.4 15.8 32.2 37.5 24.5
Public sector or non-profit facility,
including:
13.5 16.0 21.3 17.6 16.4 49.8
Public/non-profit facility 13.4 16.0 20.1 16.8 14.9 48.6
CHW 0.1 0.0 1.2 0.8 1.5 1.2
Private sector, including: 25.0 51.1 53.4 45.5 41.7 17.7
Private health facility 3.5 10.1 7.1 5.3 28.6 1.9
Pharmacy or drug store 2.8 36.5 27.1 37.1 10.4 5.3
Other private 18.7 4.5 19.3 3.1 2.7 10.5
At any time during the fever episode
Sought treatment outside of the home 50.3 73.3 78.0 72.6 71.7 77.1
Number of treatment sources (excluding home) N = 466 N = 1, 929 N = 1, 660 N = 2, 385 N = 1, 221 N = 1, 437
1 source 91.6 83.8 91.9 88.0 88.3 92.0
2 sources 7.9 15.4 7.6 11.5 11.3 7.6
3 sources 0.4 0.8 0.5 0.6 0.4 0.4
Sector mix (excluding home)
Private, no public 54.9 73.7 68.2 68.7 68.3 21.8
Public, no private 39.9 23.1 28.5 25.7 26.7 72.1
Public & private 5.2 3.3 3.2 5.6 5.0 6.1
Public sector source, among those who sought public sector
treatment
N = 210 N = 464 N = 518 N = 707 N = 385 N = 1, 094
Public/non-profit facility 98.6 100.0 94.7 95.5 91.1 98.2
CHW 1.4 0.0 5.3 5.0 9.1 2.0
Private sector source, among those who sought private sector
treatment
N = 280 N = 1, 530 N = 1, 198 N = 1, 797 N = 899 N = 432
Private health facility 22.1 26.1 16.8 13.6 74.1 13.4
Pharmacy or drug store 10.0 70.1 51.6 81.7 21.9 30.6
Other private 71.1 8.6 35.4 8.3 7.0 57.3
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Figure 1 Percentage of children under five with fever in the past two weeks that received a blood test for malaria, anti-malarial, and
ACT treatment.
Figure 2 Type of antimalarials acquired for children under five with fever in the past two weeks (N = number of anti-malarials
obtained), and most common non-artemisinin monotherapy (as % of all anti-malarials obtained).
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malarial treatments. In Benin, the public sector (41%) is
a more common source for anti-malarial drugs than the
private sector (29%), and 29% of anti-malarials are
reported to be sourced from home. A similar proportion
of anti-malarial treatments are sourced from home in
Nigeria (28%) and Uganda (20%). “At home” is a less
commonly reported source in the DRC (6%), Madagas-
car (11%) and Zambia (8%) (Figure 3).
Case management in the public and private sector
Table 3 illustrates differences in diagnosis and treatment
of fevers among children who received care either solely
in the public sector or solely in the private sector.
Across countries, public sector diagnostic testing for
malaria and treatment with anti-malarials and in parti-
cular, ACT, is low. Fewer than half of children with
fevers managed in the public sector receive a blood test
for malaria (Benin, 10%; the DRC, 28%; Madagascar,
21%; Nigeria, 14%; Uganda, 21%; and Zambia, 49%).
Public sector fever management with an ACT is also
low, particularly in Madagascar (7%), Nigeria (10%) and
the DRC (11%), and far from ideal in Benin (32%),
Uganda (47%) and Zambia (34%).
Table 2 Percentage of ACT treatments that are the
national first-line treatment
Number of ACT % first-line treatment
Benin 95 83.2
DRC 131 67.9
Madagascar 83 76.9
Nigeria 171 88.1
Uganda 360 100.0
Zambia 380 99.5
Figure 3 Source of antimalarials acquired for children under five with fever in the past two weeks (N = number of antimalarials
obtained), and most common source (as % of all anti-malarials obtained)1.
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Although levels of diagnosis and ACT treatment are
suboptimal in the public sector, fever management is
generally significantly better in the public versus private
sector. Malaria blood testing is significantly higher
among cases managed in the public sector compared to
the private sector in all study countries. Fewer than 10%
of febrile children managed in the private sector receive
diagnostic testing in Benin (2%), Madagascar (2%),
Nigeria (5%) and Zambia (7%). Diagnostic testing in the
private sector is slightly higher in the DRC (16%) and
Uganda (11%) (Table 3).
With the exception of Madagascar, treatment of fever
with any anti-malarial and with ACT is significantly
higher among children who were treated in the public
sector. In Zambia, particularly large differences are seen
in both any anti-malarial (public, 57%; private, 17%, c2
(1) = 157.8, p < 0.001) and ACT treatment (public, 34%,
private, 6%, c2(1) = 98.15, p < 0.001). Differences of a
similar scale are seen across sectors in Benin for any
anti-malarial (public, 76%; private, 44%; c2(1) = 46.82, p
< 0.001) and ACT treatment (public, 32%; private, 7%;
c2(1) = 47.59, p < 0.001). In the DRC, Nigeria and
Uganda, significant differences in any anti-malarial treat-
ment are observed across sectors, though of a less
striking magnitude. However, there are large differences
in the proportion of children receiving ACT treatment
across sectors in these countries; children seeking care
in the public sector are twice as likely to receive ACT
treatment as compared to those seeking care in the pri-
vate sector. In Uganda, the sector difference in ACT
treatment is particularly striking: nearly half of children
seeking care in the public sector received an ACT (47%)
as compared with just 12% managed in the private sec-
tor (c2(1) = 161.42, p < 0.001) (Table 3).
Diagnosis and fever treatment across socioeconomic
status
Data from Benin, the DRC, Madagascar, and Nigeria
show a pattern of inequity in ACT treatment that disad-
vantages children living in the poorest households.
However, the gradient of disparity according to signifi-
cant differences in treatment across quintiles is different
across these four countries. In Benin and the DRC, it is
children living in the wealthiest households that are sig-
nificantly different from those living in the very poorest
(Benin OR = 2.68, 95% CI = 1.12-6.42; the DRC OR =
2.18, 95% CI = 1.12-4.24). Steeper gradients of disparity
are observed in Madagascar and Nigeria, where children
Table 3 Proportion of children under five with fever receiving any anti-malarial, an ACT, and a blood test for malaria,
by treatment sector mix
N % received anti-malarial % received ACT % received blood test
Benin
Public, no private 186 76.3 31.7 9.8
Private, no public 256 43.8 6.6 2.4
c2(1)= 46.82*** 47.59*** 11.52**
DRC
Public, no private 399 67.2 11.1 27.8
Private, no public 1, 465 45.5 4.0 16.0
c2(1)= 63.70*** 31.89*** 31.18***
Madagascar
Public, no private 462 52.2 6.7 21.0
Private, no public 1142 55.2 3.2 1.8
c2(1)= 1.25 9.89 177.83***
Nigeria
Public, no private 588 47.6 9.7 14.1
Private, no public 1, 678 35.4 4.0 4.9
c2(1=) 27.97** 27.41*** 55.40***
Uganda
Public, no private 322 67.5 46.6 21.3
Private, no public 836 54.3 12.2 11.3
c2(1)= 16.97*** 161.42*** 18.76*
Zambia
Public, no private 1, 005 57.2 34.0 48.8
Private, no public 343 16.8 5.5 7.3
c2(1)= 157.83*** 98.15*** 173.01***
* p < 0.05 ** p < 0.01 *** p < 0.001
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living in households that fall within the middle of the
socioeconomic spectrum are significantly more likely to
receive ACT treatment compared to children from the
poorest households, and the relatively wealthiest chil-
dren have particularly higher advantages as compared
with the poorest (Madagascar OR = 5.37, 95% CI =
1.58-18.24; Nigeria OR = 6.59, 95% CI = 2.73-15.89)
(Table 4).
With the exception of Zambia, children living in the
wealthiest households are significantly more likely to
receive a malaria blood test compared to children in the
poorest households. The odds of receiving a diagnosis
among the wealthiest, as compared with the poorest,
ranges from 2.58 (95% CI = 1.48-4.50) in Nigeria to
11.87 (95% CI = 1.27-110.58) in Benin. Compared to the
poorest children, those living in upper-middle socioeco-
nomic status households are significantly more likely to
be tested in the DRC (OR = 3.02, 95% CI = 1.80-5.08),
Madagascar (OR = 2.99, 95% CI = 1.16-7.67) and
Uganda (OR = 2.00, 95% CI = 1.11-3.59). In the DRC,
there is a significant wealth gradient with respect to
receiving a diagnostic test (Table 4).
Caregiver familiarity with effective treatment
While the majority of caregivers in Uganda (57%) and
Zambia (81%) can correctly name the first-line anti-
malarial treatment for children under five, most care-
givers do not have such knowledge in Benin (14%), the
DRC (3%), Madagascar (4%) and Nigeria (7%). When
asked to name the most effective treatment for malaria
in children under five, nearly half of caregivers named
the first-line ACT in Zambia (49%), and 35% named the
first-line ACT in Uganda. However, very few caregivers
named the first-line treatment in Madagascar (2%), the
DRC (2%), Nigeria (4%) and Benin (10%) (Table 5).
Beyond familiarity with first-line treatments, another
indicator of caregiver knowledge and preferences is the
type of treatments requested, if and when caregivers
request specific anti-malarial treatments. Fewer than
half of caregivers report that they requested by name
the anti-malarial drugs that they acquired in Benin
(38%), the DRC (36%), Nigeria (21%), Uganda (14%) and
Zambia (8%). In Madagascar, 52% of caregivers report
requesting the treatment that they received. When care-
givers request a specific anti-malarial treatment, they
typically ask for non-artemisinin monotherapies. ACT
treatment accounts for relatively few of the treatments
requested by caregivers across countries (Benin, 11%;
the DRC, 9%; Madagascar, 5%; Nigeria, 8%; Uganda,
38%; Zambia, 23%). Artemisinin monotherapies are gen-
erally not requested, although 8% of children who
receive a requested anti-malarial in Nigeria are treated
with artemisinin monotherapy (Table 5).
Discussion
Children-in whom malarial illness can rapidly progress
to severe disease or even death-rarely receive treatment
with effective medicines. In Benin, the DRC, Madagascar
Table 4 Odds of receiving ACT and diagnostic testing by household wealth quintile, among children under five with
fever in the past two weeks
Benin DRC Madagascar Nigeria Uganda Zambia
N = 927 N = 2, 626 N = 2, 120 N = 3, 155 N = 1, 750 N = 1, 886
Received ACT
Lowest 1.00 1.00 1.00 1.00 1.00 1.00
Low 1.15
(0.55-2.39)
1.20
(0.72-2.03)
3.92
(1.35-11.41)*
1.07
(0.40-2.82)
0.62
(0.33-1.17)
0.86
(0.55-1.33)
Middle 1.55
(0.60-3.99)
1.01
(0.46-2.20)
6.75
(1.91-23.85)**
2.97
(1.13-7.83)*
0.58
(0.32-1.04)
0.81
(0.49-1.32)
High 1.30
(0.64-2.65)
1.42
(0.63-3.24)
7.25
(1.55-33.85)*
3.51
(1.44-8.59)**
0.81
(0.38-1.72)
0.47
(0.25-0.87)*
Highest 2.68
(1.12-6.42)*
2.18
(1.12-4.24)*
5.37
(1.58-18.24)**
6.59
(2.73-15.89)***
1.11
(0.56-2.20)
0.62
(0.33-1.14)
Received blood test
Lowest 1.00 1.00 1.00 1.00 1.00 1.00
Low 7.04
(0.75-65.88)
1.61
(0.94-2.76)
1.88
(0.68-5.24)
1.28
(0.63-2.62)
1.76
(0.96-3.24)
1.13
(0.82-1.54)
Middle 4.07
(0.31-53.90)
2.30
(1.41-3.76)**
1.54
(0.62-3.81)
1.19
(0.58-2.43)
1.85
(0.95-3.62)
0.94
(0.64-1.38)
High 7.91
(0.65-96.01)
3.02
(1.80-5.08)***
2.99
(1.16-7.69)*
1.45
(0.80-2.60)
2.00
(1.11-3.59)*
0.76
(0.49-1.19)
Highest 11.87
(1.27-110.58)*
5.92
(3.51-9.98)***
3.16
(1.21-8.22)*
2.58
(1.48-4.50)**
4.53
(2.37-8.64)***
1.06
(0.70-1.60)
* p < 0.05 ** p < 0.01 *** p < 0.001
Littrell et al. Malaria Journal 2011, 10:327
http://www.malariajournal.com/content/10/1/327
Page 9 of 14
Table 5 Familiarity with and preferences for effective treatment among caregivers of children under five with fever in the past two weeks
Benin DRC Madagascar Nigeria Uganda Zambia
N = 885 N = 2, 331 N = 1, 970 N = 2, 833 N = 1, 452 N = 1, 727
% Caregivers who name the national first-line drug when asked to list anti-malarials that they have heard of 13.5 3.1 3.5 6.9 57.2 81.1
% Caregivers who name the national first-line drug as the most effective anti-malarial for children under five 9.8 2.0 1.8 4.3 35.1 49.2
N = 381 N = 1, 186 N = 965 N = 1, 097 N = 898 N = 709
% Children treated with an anti-malarial that received a drug requested by their caregiver 37.5 35.8 51.9 21.3 14.1 7.9
Type of anti-malarial received, among children that received an anti-malarial requested by caregiver1 N = 143 N = 450 N = 549 N = 238 N = 127 N = 57
% Non-artemisinin
monotherapy
91.6 88.4 95.7 87.8 63.0 75.0
% ACT 10.5 9.2 4.7 7.6 38.1 22.6
% Artemisinin monotherapy 0.0 3.1 n/a 7.6 0.6 2.4
1 Categories are not mutually exclusive as some children received more than one anti-malarial
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and Nigeria, ACT treatment is not only uncommon, it is
inequitable. Children living in the relatively wealthiest
households are more likely to receive effective fever
treatment compared to children from the poorest
households. In Zambia and Uganda, countries with
much higher coverage of treatment with an ACT, still
only one in five children with fever received ACT treat-
ment. However, in these countries ACT treatment is
not associated with household socioeconomic status.
Successful strategies to increase access to ACT in envir-
onments of relative political and economic stability are
perhaps what set these countries apart.
Zambia was one of the first African countries to
change its first-line policy to ACT treatment. Policy
change in 2002 was followed rapidly by implementation
in 2003 and national scale-up focused on the public
health system in 2004. While barriers to accessing pub-
lic health care in rural areas still exist, the financial bar-
rier that user fees presented was removed in 2006
[13-15]. Furthermore, substantial investment has been
made since 2000 by donors, including USAID/Presi-
dent’s Malaria Initiative (PMI), GFATM (the Global
Fund to Fight AIDS, Tuberculosis and Malaria), the
World Bank, and the Bill and Melinda Gates Foundation
support through the MACEPA (Malaria Control and
Evaluation Partnership in Africa) programme at PATH
[7,13].
In Uganda, case management has been strengthened
in both the public and private sectors. Government
health facility user fees were removed in 2001 followed
by an initial increase in utilization of care [16]. The
first-line therapy for uncomplicated malaria was chan-
ged to the ACT artemether-lumefantrine (AL) in 2004.
Pre-packaged AL is provided in public and not-for-profit
facilities free of charge. A national home-based manage-
ment of fever programme was launched in 2002 and
modified towards integrated community case manage-
ment in 2010 [17]. In the private sector, a subsidy pilot
launched in 2008 in two districts by the Ministry of
Health and the Medicines for Malaria Venture suc-
ceeded in improving the availability and reducing the
price of ACT [18]. It appears that equitable gains have
been achieved in roll-out and scale up of subsidized
ACT in the public sector in Zambia and across sectors
in Uganda. While a socioeconomic gradient exists in
study countries with lower levels of coverage, higher
coverage achieved in Zambia and Uganda may contri-
bute to an equitable diffusion to the lower socioeco-
nomic groups that has been observed with high levels of
coverage (higher than Zambia and Uganda have yet
achieved) [19].
While donor funding for malaria control began to
increase in Zambia in 2000 and in Uganda in 2004, sub-
stantial donor investment began a bit later in other
study countries-in 2005 for the DRC, Nigeria and Mada-
gascar, and in 2007 for Benin [7]. Free public sector
provision of ACT treatment was only declared policy in
Nigeria in 2009 (the year of the survey), in Madagascar
in 2006, and is not yet policy in Benin or the DRC [7].
A private-sector, subsidized ACT programme was
launched by Population Services International (PSI) just
before the 2008-09 survey in Madagascar. In Nigeria,
private-sector, subsidized ACT programmes were first
launched by Society for Family Health with funding
from the GFATM in 2008 (the year prior to the survey).
Public and private sector initiatives supported by
increased donor funding in Benin, the DRC, Nigeria and
Madagascar appear to have not yet achieved the relative
scale and equitable gains observed in Uganda and Zam-
bia. Additional time and investment may be needed in
these countries. Political and economic instability may
also be playing a role in the DRC, Nigeria and
Madagascar.
Further improvement is needed for effective fever
treatment among those who seek care in both the pri-
vate and public sectors across study countries. Imple-
mentation of national malaria control policies in the
public sector (which in this study is largely comprised
of facility-based care as opposed to CHW care),
although relatively better than in the private sector, is
far from universal. While nearly half of children mana-
ged in the public sector in Zambia receive a diagnostic
test, testing in the public sector is far lower in all
other study countries, ranging from one in ten in
Benin to one in four in the DRC. First-line treatment
using an ACT has been national policy since 2002 in
Zambia; 2004 in Benin, Nigeria and Uganda; 2005 in
the DRC; and 2006 in Madagascar. Nevertheless, treat-
ment of fever with an ACT in the public sector is
strikingly low in Madagascar (7%), Nigeria (10%) and
the DRC (11%), and is far from ideal in Benin (32%),
Zambia (34%) and Uganda (47%). Case management
practices that do not adhere to national policies have
been documented among public health systems in sub-
Saharan Africa in a number of studies [20-24]. There
is little information on what works to improve provi-
der practices in the public sector [25]. Effective pro-
curement and drug supply management must be in
place, including continuous stock of the national first-
line drug, as well as absence of ineffective drugs that
should not be used to treat malaria. However, supply
of effective medicines does not necessarily translate
into their use [25-27]. Several studies suggest that
training is not adequate to improve provider practices
[22,25,26,28,29], even when coupled with job aids
[28,29]. Factors including quality of training; integrated
rather than vertical training approaches; and quality
supervision are thought to be important
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[22,23,25-27,29,30]. However, there are a number of
other factors that may influence provider practices
including health worker motivations and perceptions;
client factors (e.g. severity of illness, client demands);
working environment (e.g. leadership, peers, location,
supplies, administration, educational opportunities,
competing opportunities); community perceptions,
sociocultural traditions and values; and the political
and economic environment. Given the myriad of fac-
tors with potential to influence behaviour, simply
training providers on new guidelines-even when per-
fectly comprehended, may not translate into provider
behaviour change [30]. Interventions far more complex
than training and job aid may be necessary. However,
these will involve tackling the larger issues that plague
public health systems in many developing countries.
Across six countries in sub-Saharan Africa, this study
finds that when caregivers search for fever treatment out-
side of the home they typically visit one outlet [31]. With
the exception of Zambia, this outlet is most often part of
the private sector. Previous studies have shown that across
a range of settings, the private sector is preferred by care-
givers seeking treatment given ease of access, reliable drug
supply, familiarity with staff, and perceptions around flex-
ible and/or affordable prices [3]. Given that on average,
only one drug outlet will be visited, the type of treatments
and quality of care available at that outlet are key factors
in determining whether or not a child will receive effective
treatment. While caregivers often rely on the private sec-
tor when seeking treatment, results suggest that fevers are
typically more appropriately managed in the public sector.
In all countries except Madagascar, children who are trea-
ted solely in the public sector are significantly more likely
to receive a blood test for malaria and to receive ACT
treatment than children who were treated solely in the pri-
vate sector. Given patterns of caregiver treatment-seeking
behaviours that favour the private sector [1], one of the
key opportunities to improve fever management in malaria
endemic sub-Saharan Africa is to target the private sector.
Results from this study show that the types of outlets that
dominate private sector treatment-seeking for fever vary
across countries. Among those seeking treatment in the
private sector, pharmacies and drug shops are more com-
monly accessed in the DRC, Madagascar and Nigeria.
Other outlet types such as shops, kiosks and mobile ven-
dors are more commonly accessed in Benin and Zambia.
In Uganda, private health facilities are the most commonly
accessed private sector outlet. These results suggest that
targeting the private sector to improve fever case manage-
ment requires context-specific knowledge of the key out-
lets that are most often visited by children’s caregivers for
fever treatment.
What exactly is needed to improve case management
in the private sector? This study of household
treatment-seeking behaviour is limited in the definitive
conclusions that can be reached. Results from the ACT-
watch outlet surveys highlight private sector barriers of
availability and price. Across the countries included in
this study, ACT availability is significantly lower in the
private sector compared to the public sector. Further-
more, when available in the private sector, ACT tends
to be substantially more expensive than non-artemisinin
monotherapies [6]. Provider practices are also important
to consider, particularly as ACT accessibility improves
[32-36]. The ACTwatch outlet surveys found that, on
average, private-sector provider familiarity with the first-
line treatment for uncomplicated malaria is significantly
lower than knowledge among public providers, and
fewer than half of private providers in all six countries
can describe the dosing regimen of the first-line treat-
ment for a two-year old child [6]. To leverage the
opportunity that the private sector presents for improv-
ing fever treatment, both access and provider training
are likely to be important. Factors that influence private
providers are likely to be different from those that are
influential for public sector provider behaviour [30].
Strategies to improve case management will need to
include interventions targeted at the unique barriers to
appropriate case management among private providers.
Informed demand among children’s caregivers may
also be a key area for improving fever management in
the context of improved private sector access [33-36].
Results from this study illustrate low levels of awareness
of the first-line treatment among caregivers, meaning
that in the search for fever treatment, they are unlikely
to be seeking the first-line drug. Caregivers request anti-
malarial medicines by name to varying degrees across
countries. However, when they do so, they typically
request ineffective medicines, such as chloroquine.
Greater demand for ACT among caregivers could
translate to increased market share for these effective
treatments, where they are readily available and afford-
able. Results point to other areas in which informed
demand could have a positive impact. Across all coun-
tries, treatment is not sought outside of the home for
about a quarter of all fevers in children under five. In
the case of Benin, half of the children are treated exclu-
sively at home. These results suggest the need for tar-
geted communications around prompt fever treatment
with effective medicines that speak to context-specific
factors inhibiting existing treatment-seeking behaviour.
’At home’ was a frequently cited source for anti-
malarial drugs in Benin and Uganda. There is need to
understand better what anti-malarial treatment at home
entails: are these medicines that have been used to treat
a prior illness, in which case there is possibility of
incomplete dosing [1], or medicines purchased and
stored at home in advance of illness? In addition to
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creating demand for specific medicines, there may be
need for further communication around adherence to
full-course treatments.
Communications to raise caregiver awareness and
additional provider training may also be needed as diag-
nostic testing becomes more widely accessible. There
will also be need to examine treatment according to
diagnostic test results. In this study, blood testing for
malaria was generally uncommon and presumptive
treatment was still the most informative indicator with
respect to fever management. However, WHO policy
(2010) recommends parasitological confirmation by
microscopy or RDT in all cases of suspected malaria
prior to treatment, where diagnostic testing is accessible
[37]. In Zambia, the proportion of cases that receive a
malaria blood test is slightly higher and approaching
50% among children treated in the public sector. As
levels of malaria diagnostic testing rise, presumptive
treatment indicators are no longer as informative, given
that appropriate treatment of confirmed negative cases
must be taken into account. Future studies should focus
on describing treatment actions taken according to diag-
nostic test results. However, bias in caregiver recall of
test results is likely to present formidable challenges to
this type of measurement, and other methodologies may
be needed including routine monitoring systems in the
public and private sectors where relevant.
This study aimed to provide key treatment-seeking
indicators across countries prior to large-scale efforts to
improve access to effective treatment. The nationally
representative ACTwatch household surveys used stan-
dardized methodologies across countries and collected
detailed information about treatment-seeking behaviour.
Corresponding supply-side data, including availability
and price, is available from the ACTwatch outlet surveys
[6]. These data provide important context to household
treatment-seeking behaviour results. Study limitations
include reliance on caregiver reports regarding actions
taken to treat fever in children. Recall bias was mini-
mized in this study by employing a standard two-week
recall period, and using visual aids to prompt identifica-
tion of treatments acquired for children.
Household survey methodology in and of itself is lim-
iting and often leads to more questions than answers
regarding treatment-seeking behaviour. Questions raised
in this study include the need for further exploration of
the use of anti-malarial medicines that are stored at
home. Results show that children treated in the private
sector are less likely to receive appropriate diagnostic
testing and treatment as compared with children treated
in the public sector. Nonetheless, proper case manage-
ment of fever in the public sector is far from ideal.
More information on consumer and provider practices
could guide interventions to address both public and
private sector deficiencies. Where interventions are
developed and implemented, the need for evaluation is
great. At present, limited evidence is available on what
works for improving provider practices [23,30] and
increasing informed demand among caregivers [38].
Additionally, as interventions aiming to increase access
to ACT are scaled up, equitable access to treatment
monitored through household surveys will be an impor-
tant indicator of success [39].
Conclusions
Improved access to ACT is needed in order to achieve
equitable gains in effective fever treatment. Treatment-
seeking patterns show that the private sector is fre-
quently accessed for fever treatment, and thus could be
an important resource for improving access to effective
treatment. However, private sector case management
practices are relatively poor in comparison with the
public sector. Interventions targeting provider practices
in both the public and private sectors are needed to
support efforts at improving access to ACT. Demand
creation targeted at children’s caregivers is also an
important supporting intervention. As the AMFm and
other interventions focused on increased access to ACT
scale up, it will be important to monitor the extent to
which gains in prompt and effective fever treatment are
shared across socioeconomic groups. Additionally, mon-
itoring case management performance in the public and
private sectors will be key in evaluating the success of
supply-side investments.
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